ArticleBMC neurology2026
Levodopa intolerance as a potential clinical red flag for neuronal intranuclear inclusion disease (NIID) in atypical parkinsonism: a case report.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuronal intranuclear inclusion disease (NIID) is a rare, progressive multisystem disorder most commonly associated with GGC repeat expansion in the NOTCH2NLC gene. Parkinsonism can be an initial presentation and may be misdiagnosed as idiopathic Parkinson's disease, particularly when prominent non-motor features are present. While many cases are levodopa-responsive, diagnosis is challenging when prominent non-motor features and drug intolerance are present. CASE PRESENTATION: We report a case of a 70-year-old woman of Han Chinese who developed atypical parkinsonism, severe cognitive decline, and severe gastrointestinal dysfunction. A therapeutic trial of levodopa/benserazide produced only minimal and transient motor benefit but resulted in marked worsening of nausea and vomiting, precluding dose escalation. Brain MRI demonstrated a characteristic corticomedullary junction (CMJ) hyperintensity on diffusion-weighted imaging. Skin biopsy revealed intranuclear inclusions on electron microscopy, and genetic testing confirmed pathogenic GGC repeat expansion in NOTCH2NLC, establishing the diagnosis of NIID.
conclusionsThis case highlights that profound levodopa intolerance in patients with atypical parkinsonism, especially when accompanied by severe gastrointestinal dysfunction and early cognitive decline, should prompt consideration of NIID. Early recognition of this clinical pattern, together with characteristic MRI findings and confirmatory pathology/genetics, may help reduce diagnostic delay and facilitate timely multidisciplinary supportive care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.